<DOC>
	<DOCNO>NCT00915343</DOCNO>
	<brief_summary>This randomise , control , open , two-armed , two-period cross-over , multi-centre phase II/III study ass safety , tolerability pharmacokinetics once-daily oral modified-release hydrocortisone comparison conventional thrice-daily oral hydrocortisone tablet patient adrenal insufficiency</brief_summary>
	<brief_title>Once-daily Oral Modified Release Hydrocortisone Patients With Adrenal Insufficiency</brief_title>
	<detailed_description>Adrenal insufficiency disease 80 % 1-year mortality availability synthetic glucocorticoid . Current replacement therapy improve dramatically , recent data suggest outcome still compromise . Patient receive replacement therapy hydrocortisone cortisone acetate compromise quality life , reduce bone mass , increase risk factor cardiovascular disease premature mortality twice mortality rate background population . Circulating cortisol level follow distinct diurnal pattern high level early morning low trough value around midnight . Using available formulation replacement therapy circadian rhythm mimic also active time day high peak low trough occur . In trial newly develop novel dual- , control release formulation hydrocortisone healthy volunteer able mimic circadian pattern circulate cortisol study patient primary adrenal insufficiency ( Addison 's disease ) .</detailed_description>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Previously diagnose ( e.g . 6 month ago ) primary adrenal insufficiency stable daily glucocorticoid substitution dose least 3 month prior study entry Signed informed consent participate study . Clinical laboratory sign significant cerebral , cardiovascular , respiratory , Hepatobiliary , pancreatic disease Clinically significant renal dysfunction Clinical laboratory sign significant gastrointestinal empty motility disease Any medication agent could interfere hydrocortisone kinetics Pregnant lactate woman Regular dehydroepiandrosterone ( DHEA ) medication past 4 week Oral oestrogen medication past 4 week Deranged mineralocorticoid status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Adrenal insufficiency</keyword>
	<keyword>Primary adrenal insufficiency</keyword>
	<keyword>Addison 's disease</keyword>
	<keyword>Hydrocortisone</keyword>
	<keyword>Modified release</keyword>
</DOC>